ALZpath inks agreement with Roche for use of antibody in blood test to diagnose Alzheimer's Disease

US-based ALZpath, Inc., a leading developer of innovative diagnostic tools and solutions for Alzheimer's disease and related dementias, has announced a strategic license agreement with Swiss firm Roche for use of the ALZpath pTau217 antibody to develop and commercialise an Alzheimer's disease diagnostic blood test that will be offered on the Roche Elecsys® platform.

The Roche pTau217 test was recently granted Breakthrough Device designation by the US FDA and will be commercialised as a part of an ongoing collaboration between Roche and Eli Lilly.

pTau217 is a critical biomarker for detecting the presence and progression of Alzheimer's disease in blood. Blood-based assays using ALZpath's pTau217 antibody have been shown to provide the same accuracy and reliability as more expensive and invasive PET imaging or cerebral spinal fluid (CSF) testing, but with the affordability and convenience of a simple, less invasive blood test.

Alzheimer's disease and related dementias are expected to impact close to 140 million individuals by 2050. Access to faster, affordable, and more reliable and accurate testing will be critical to address the needs of patients and their families. ALZpath is democratizing access to its proprietary pTau217 antibody, which can be used across a variety of clinical and research settings.

As promising treatments for Alzheimer's disease emerge, ALZpath is pursuing strategic partnerships with global diagnostic leaders to make available its technology to laboratories worldwide.